IGC Pharma, Inc. (NYSE:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.
Dr. Carl Griffin, MD, will serve as the Principal Investigator for the site. Dr. Griffin brings extensive experience in conducting clinical trials and a deep commitment to improving outcomes for patients affected by neurodegenerative diseases. He and the team at LHSI will begin recruiting eligible patients immediately.
"Expanding our clinical footprint to Oklahoma represents another important step toward reaching more patients and families affected by this devastating condition," said Ram Mukunda, CEO of IGC Pharma. "We are pleased to welcome Dr. Griffin and the Lynn Health Science Institute to the CALMA trial and look forward to their contributions in advancing our mission."